ANDA 75253, held by Actavis Elizabeth. Ticlopidine Hydrochloride.
As of Nov 16, 2026, ANDA 75253 (Ticlopidine Hydrochloride), held by Actavis Elizabeth, was first approved by FDA on Aug 20, 1999, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 20, 1999 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ticlopidine Hydrochloride250MG ยท tablet;oral | Ticlopidine Hydrochloride | Discontinued |
| Nov 5, 2002 | Supplement 7Manufacturing | Approved | None posted |
| Feb 15, 2002 | Supplement 6Labeling | Approved | None posted |
| Nov 13, 2001 | Supplement 5Manufacturing | Approved | None posted |
| Nov 2, 2001 | Supplement 4Manufacturing | Approved | None posted |
| Feb 20, 2001 | Supplement 3Manufacturing | Approved | None posted |
| Jan 17, 2001 | Supplement 2Labeling | Approved | None posted |
| Nov 9, 2000 | Supplement 1Manufacturing | Approved | None posted |
| Aug 20, 1999 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters